Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Pulido

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
Nature Medicine|November 19, 2013
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceTimothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 2, 2008
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancerTimothy Kottke, Rosa M Diaz, Karen Kaluza, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 26, 2014
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical siteVanesa Alonso-Camino, Karishma Rajani, Timothy Kottke, et al.
Molecular Therapy Oncolytics|December 10, 2016
Immunogenicity of self tumor associated proteins is enhanced through protein truncationTim Kottke, Kevin G Shim, Vanesa Alonso-Camino, et al.
Research Square|November 28, 2024
Cancer Immunotherapy Using AIRE Conditioning of the Tumor EpitopeomeRichard Vile, Jose Pulido, Alex Chen, et al.
Research Square|March 22, 2023
MicroMagnify: a multiplexed expansion microscopy method for pathogens and infected tissuesYongxin Zhao, Zhangyu Cheng, Caroline Stefani, et al.
Blood|September 29, 2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaHan W Tun, Patrick B Johnston, Lisa M DeAngelis, et al.
Nature Communications|June 26, 2020
Oncolytic virus-derived type I interferon restricts CAR T cell therapyLaura Evgin, Amanda L Huff, Phonphimon Wongthida, et al.
Science Translational Medicine|April 13, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in miceLaura Evgin, Tim Kottke, Jason Tonne, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
Nature Medicine|November 19, 2013
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceTimothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 2, 2008
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancerTimothy Kottke, Rosa M Diaz, Karen Kaluza, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 26, 2014
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical siteVanesa Alonso-Camino, Karishma Rajani, Timothy Kottke, et al.
Molecular Therapy Oncolytics|December 10, 2016
Immunogenicity of self tumor associated proteins is enhanced through protein truncationTim Kottke, Kevin G Shim, Vanesa Alonso-Camino, et al.
Research Square|November 28, 2024
Cancer Immunotherapy Using AIRE Conditioning of the Tumor EpitopeomeRichard Vile, Jose Pulido, Alex Chen, et al.
Research Square|March 22, 2023
MicroMagnify: a multiplexed expansion microscopy method for pathogens and infected tissuesYongxin Zhao, Zhangyu Cheng, Caroline Stefani, et al.
Blood|September 29, 2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaHan W Tun, Patrick B Johnston, Lisa M DeAngelis, et al.
Nature Communications|June 26, 2020
Oncolytic virus-derived type I interferon restricts CAR T cell therapyLaura Evgin, Amanda L Huff, Phonphimon Wongthida, et al.
Science Translational Medicine|April 13, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in miceLaura Evgin, Tim Kottke, Jason Tonne, et al.
Pageof 7